Vor Biopharma upgraded by Robert W. Baird with a new price target
$VOR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Robert W. Baird upgraded Vor Biopharma from Neutral to Outperform and set a new price target of $64.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/15/2025 | $64.00 | Neutral → Outperform | Robert W. Baird |
| 9/24/2025 | $55.00 | Hold → Buy | Stifel |
| 6/30/2025 | $3.00 | Neutral → Buy | H.C. Wainwright |
| 7/26/2022 | $18.00 | Outperform | Wedbush |
| 4/27/2022 | $6.00 | Neutral | Goldman |
| 12/17/2021 | $26.00 | Buy | HC Wainwright & Co. |
| 12/3/2021 | $38.00 | Outperform | Robert W. Baird |
| 12/3/2021 | $38.00 | Outperform | Baird |
Robert W. Baird upgraded Vor Biopharma from Neutral to Outperform and set a new price target of $64.00
Stifel upgraded Vor Biopharma from Hold to Buy and set a new price target of $55.00
H.C. Wainwright upgraded Vor Biopharma from Neutral to Buy and set a new price target of $3.00
4 - Vor Biopharma Inc. (0001817229) (Issuer)
4 - Vor Biopharma Inc. (0001817229) (Issuer)
4 - Vor Biopharma Inc. (0001817229) (Issuer)
4 - Vor Biopharma Inc. (0001817229) (Issuer)
144 - Vor Biopharma Inc. (0001817229) (Subject)
144 - Vor Biopharma Inc. (0001817229) (Subject)
144 - Vor Biopharma Inc. (0001817229) (Subject)
CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from Stage A of a Phase 3 study in China sponsored by Vor Bio's collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), which evaluated telitacicept in adults with IgA neuropathy (IgAN), will be presented as a late-breaking oral presentation at American Society of Nephrology's (ASN) Kidney Week 2025 being held Nov 5-9, 2025, in Houston, Texas. Late-Breaking Oral Presentation Details Abstract Title: Efficacy and Safety of Telitacicept in Patients with lgA Nephropathy: Results from Stage A of
Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7% with placebo Dual inhibition of BAFF and APRIL validated as a transformative B-cell approach, highlighting telitecicept's potential as a disease-modifying therapy for systemic lupus erythematosus BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that results from a Phase 3 study in China evaluating telitacicept in systemic lupus erythematosus (SLE) sponsored by its collaborator, RemeGen Co., Ltd., (HKEX: 9995,
Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved ≥3-point ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index) reduction vs 19.3% on placebo at 24 weeks Sustained efficacy and favorable safety profile through 48 weeks support potential best-in-disease profile in primary Sjögren's disease (pSD) Company evaluating timing of global Phase 3 clinical study in primary Sjögren's diseaseVor Bio to host a conference call on Tuesday, October 28, 2025 at 4:30PM ET BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-sta
CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer. Dr. Khan joins Vor Bio with over two decades of experience spanning medical affairs, commercial, and R&D functions. He has overseen more than 40 development programs in neurology, immunology, and infectious diseases, and successfully guided seven U.S. and global product launches in rare neurology and immunology indications. Most recently, Dr. Khan was Head of Neuromuscular Therapeutic Area, Medical Affairs at argenx, where h
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Adi Osovsky, S.J.D. as General Counsel. Dr. Osovsky brings 17 years of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. "We are delighted to welcome Adi to Vor Bio at this important stage in our growth," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "Adi's proven experience advising public biopharmaceutical companies on governance, compliance, and strategic transactions makes her an outstanding addition to our leadersh
CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Dallan Murray as Chief Commercial Officer, effective immediately. "We're thrilled to welcome Dallan to Vor Bio at this important inflection point," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "His track record of building high-performing commercial organizations and executing successful product launches will be instrumental as we prepare for potential commercialization of telitacicept and shape our broader growth strategy." Mr. Murray brings more than 25 yea
Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved ≥3-point ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index) reduction vs 19.3% on placebo at 24 weeks Sustained efficacy and favorable safety profile through 48 weeks support potential best-in-disease profile in primary Sjögren's disease (pSD) Company evaluating timing of global Phase 3 clinical study in primary Sjögren's diseaseVor Bio to host a conference call on Tuesday, October 28, 2025 at 4:30PM ET BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-sta
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value. These strategic alternatives could include, among other alternatives, a potential sale of assets of the Company, a potential licensing of assets of the Company, a sale of the Company, a business combination, a merger or other strategic action. The Company
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic windowCompany has received supportive feedback from the FDA regarding a registrational clinical trial design CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data, which was presented in a post
SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)
SC 13D/A - Vor Biopharma Inc. (0001817229) (Subject)
SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)